M&A Deal Summary

Genzyme Acquires Bone Care International

On July 1, 2005, Genzyme acquired life science company Bone Care International for 719M USD

Acquisition Highlights
  • This is Genzyme’s 7th transaction in the Life Science sector.
  • This is Genzyme’s 3rd largest (disclosed) transaction.
  • This is Genzyme’s 8th transaction in the United States.
  • This is Genzyme’s 1st transaction in Wisconsin.

M&A Deal Summary
Date 2005-07-01
Target Bone Care International
Sector Life Science
Buyer(s) Genzyme
Deal Type Add-on Acquisition
Deal Value 719M USD
Advisor(s) Citigroup Investment Banking (Financial)

Target

Bone Care International

Middleton, Wisconsin, United States
Bone Care International, Inc. is a bio-pharmaceutical company.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genzyme

Cambridge, Massachusetts, United States
Category Company
Founded 1981
Sector Life Science
DESCRIPTION
Genzyme laboratory in Framingham, Massachusetts.
Genzyme laboratory in Framingham, Massachusetts.

Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 9 of 12
Sector (Life Science) 7 of 9
Type (Add-on Acquisition) 8 of 10
State (Wisconsin) 1 of 1
Country (United States) 8 of 9
Year (2005) 2 of 2
Size (of disclosed) 3 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-02-28 Verigen AG

Leverkusen, Germany

Verigen AG, a private company based in Germany with a proprietary cell therapy product for cartilage repair currently sold in Europe and Australia.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-10-17 AnorMED

Langley, British Columbia, Canada

AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, oncology and HIV, based on the Company's research into chemokine receptors.

Buy $580M
Mergr

Product

Company

Legal